Overexpression of metallothionein confers resistance to anticancer drugs

Susan L. Kelley, Alakananda Basu, Beverly A. Teicher, Miles P. Hacker, Dean H. Hamer, John S. Lazo

Research output: Contribution to journalArticle

595 Scopus citations

Abstract

Resistance to antineoplastic agents is the major obstacle to curative therapy of cancer. Tumor cell lines with acquired resistance to the antineoplastic agent cis-diamminedichloroplatinum(II) overexpressed metallothionein and demonstrated cross-resistance to alkylating agents such as chlorambucil and melphalan. Human carcinoma cells that maintained high levels of metallothionein because of chronic exposure to heavy metals were resistant to cis-diamminedichloroplatinum(II), melphalan, and chlorambucil. Furthermore, cells transfected with bovine papilloma virus expression vectors containing DNA encoding human metallothionein-IIA were resistant to cis-diamminedichloroplatinum(II), melphalan, and chlorambucil but not to 5-fluorouracil or vincristine. Thus, overexpression of metallothionein represents one mechanism of resistance to a subset of clinically important anticancer drugs.

Original languageEnglish
Pages (from-to)1813-1815
Number of pages3
JournalScience
Volume241
Issue number4874
DOIs
StatePublished - 1 Jan 1988

Fingerprint Dive into the research topics of 'Overexpression of metallothionein confers resistance to anticancer drugs'. Together they form a unique fingerprint.

  • Cite this

    Kelley, S. L., Basu, A., Teicher, B. A., Hacker, M. P., Hamer, D. H., & Lazo, J. S. (1988). Overexpression of metallothionein confers resistance to anticancer drugs. Science, 241(4874), 1813-1815. https://doi.org/10.1126/science.3175622